1.           Schmid U, Weber B, Dallinger C, Richeldi L, Hallmann C, Raghu G, Freiwald M. Relationship between nintedanib exposure, clinical efficacy and adverse events in patients with idiopathic pulmonary fibrosis (IPF).  2016 ACoP; Bellevue, WA.

 

2.           Schmid U, Weber B, Dallinger C, Richeldi L, Hallmann C, Raghu G, Freiwald M. Relationship between nintedanib exposure, patient characteristics and clinical efficacy in patients with idiopathic pulmonary fibrosis.  2016 ATS Congress; San Francisco, CA.

 

3.           Schmid U, Weber B, Dallinger C, Luca Richeldi, Hallmann C, Raghu G, Freiwald M. Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis.  ERS Internation Congress 2016; London, United Kingdom.

 

4.           Bateman E, Mackie A, Benediktus E, Schepers C, Kim JM, Tadayasu Y, Lee G, Wood C, Weber B. Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist.  ERS International Congress 2016; London, UK.

 

5.           Weber B, Borghardt JM. New Insights in the Pulmonary Fate of Inhaled Drugs.  2015 PAGE Meeting; Hersonissos, Greece.

 

6.           Sharma A, Weber B, Stopfer P, Borghardt JM, Rapp B, Schmid M, Hallmann C, Moroni-Zentgraf P. Tiotropium Pharmacokinetics in Patients with Asthma - A Pooled Analysis.  2015 ACCP Meeting; San Francisco, CA.

 

7.           Schilling U, Miesler T, Weber B, Hochhaus G. A Semi-Mechanistic Model for Predicting the Nasal and Plasma Pharmacokinetics of Intranasal Corticosteroids.  2015 ACCP Meeting; San Francisco, CA.

 

8.           Miesler T, Schilling U, Weber B, Hochhaus G. An open-source, user-friendly simulation tool to predict the pharmacokinetics of inhaled corticosteroids.  2015 ACCP Meeting; San Francisco, CA.

 

9.           Borghardt JM, Weber B, Staab A, Kunz C, Schiewe J, Kloft C. The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol.  2015 PAGE Meeting; Hersonissos, Greece.

 

10.         Borghardt JM, Weber B, Staab A, Kloft C. A New Parameterisation to Describe Parallel Absorption Processes After Drug Inhalation.  2015 PAGE Meeting; Hersonissos, Greece.

 

11.         Parra-Guillen Z, Weber B, Sharma A, Freijer J, Retlich S, Borghardt J, Troconiz I. Population Pharmacokinetic Analysis of Tiotropium in Healthy Volunteers after Intravenous Administration and Inhalation.  2014 ACoP Las Vegas, NV.

 

12.         Borghardt J, Weber B, Staab A, Kunz C, Schiewe J, Kloft C. The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol.  PAGE 2014; Alicante, Spain.

 

13.         Zhao L, Weber B, Hochhaus G. A Simulation Tool for Evaluating EMAs Regulatory PK Limits for Bioequivalence Testing of Inhaled Corticosteroids.  2013 ACCP Meeting; Bethesda, MD.

 

14.         Kandala B, Weber B, Winner L, Hochhaus G. Evaluation of the Feasibility of Pharmacodynamic Bioequivalence Studies of Inhaled Corticosteroids through Monte Carlo Simulations.  ISAM 2013; Chapel Hill, NC.

 

15.         Kandala B, Weber B, Winner L, Hochhaus G. Power Calculations for Pharmacodynamic Crossover Studies Conducted to establish Bioequivalence of Inhaled Corticosteroids Through Monte Carlo Simulations.  2013 ACoP; Ft. Lauderdale, FL.

 

16.         Kandala B, Weber B, Joseph R, Maas B, Hochhaus G. A New Simulation Model to Assess the Power of Pharmacodynamic Crossover Studies Conducted to Establish Bioequivalence of Orally Inhaled Drug Products.  2013 ACCP Meeting; Bethesda, MD.

 

17.         Hurtado F, Zimmermann E, Weber B, Derendorf H, Dalla Costa T. Free Levooxacin Concentrations in Prostate and Lung Modeled by a Population Pharmacokinetic Approach.  7th International Symposium on Microdialysis; Poitiers, France

 

18.         Weber B, Hochhaus G. A Clinical Trial Simulation Tool for the Suppression of the Endogenous Cortisol Release after Administration of Inhaled Corticosteroids.  2012 GPEN Meeting Melbourne, Australia.

 

19.         Hurtado F, Weber B, Derendorf H, Dalla Costa T. Population Pharmacokinetic Modeling of the Unbound Levooxacin Concentrations in Plasma and Prostate Tissue Measured by Microdialysis in Rats.  4th Meeting of the Pharmaceutical Sciences Graduate Program; Porto Alegre, Brazil.

 

20.         Haug KG, Weber B, Derendorf H, Butterweck V. Characterization of the pharmacokinetic properties of visnagin and Ammi visnaga water extract following oral administration in rats.  DPhG Jahrestagung 2012; Greifswald, Germany.

 

21.         Weber B, Adams W, Lionberger R, Li B, Tsong Y, Hochhaus G, Lee S. Evaluation of Statistical Methods for Determining Equivalence of Aerodynamic Particle Size Distribution.  2011 AAPS Annual Meeting; Washington, DC.

 

22.         Weber B, Goyal N, Kandala B, Hochhaus G. Simulation-based evaluation of tmax as a pharmacokinetic parameter to assess bioequivalence of inhaled corticosteroids.  2010 ACCP Meeting; Baltimore, MD.

 

23.         Weber B, Goyal N, Hochhaus G. Simulation-based evaluation of tmax as a pharmacokinetic parameter to assess bioequivalence of inhaled corticosteroids.  23rd Annual Research Showcase and Awards Recognition Day at University of Florida; Gainesville, FL.

 

24.         Kandala B, Weber B, Hochhaus G. Clinical Trial Simulations Using an Improved Inhalation Model to Evaluate the Potential of Pharmacokinetic Studies in Establishing Bioequivalence of Inhaled Corticosteroids.  2010 APPS Annual Meeting; New Orleans, LA.

 

25.         Weber B, Wu K, Blomgren A, Ekholm K, Edsbaecker S, Hochhaus G. Effect of protein binding on pulmonary corticosteroid receptor occupancy.  7th Retrometabolism Based Drug Design and Targeting Conference; Orlando, FL.

 

26.         Goyal N, Weber B, Hochhaus G. Bioequivalence of Inhaled Corticosteroids - A Pharmacokinetic Approach.  7th Retrometabolism Based Drug Design and Targeting Conference; Orlando, FL.